Aug 23, 2012 by Max Macaluso3 Reasons Pfizer Should Partner With MannKindShould Pfizer try again to enter the inhalable insulin market?
Aug 21, 2012 by Max Macaluso1 Drug Company That Can Take You from Rags to RichesPerrigo Pharmaceuticals reported impressive quarterly earnings last week -- but is it a good long-term investment?
Aug 15, 2012 by Max MacalusoShould You Buy This Revolutionary Biotech Stock?OraSure's over-the-counter HIV test is a leap forward for public health -- but is this company a good investment?
Aug 8, 2012 by Max Macaluso1 Innovative Retailer for Your PortfolioHSN released another solid quarterly earnings report. Is now the time to buy this progressive retailer?
Aug 6, 2012 by Max MacalusoHow Impax Labs Can Impact Your PortfolioImpax Labs had impressive quarterly earnings, but is it a good addition to your portfolio?
Aug 1, 2012 by Max MacalusoHow Margins Rescued This Defense StockDefense contractor Raytheon released its Q2 2012 results last week, and it looks like better margins saved the day.
Aug 1, 2012 by Max MacalusoIs Your Portfolio Too Cool for School?TAL Education shares dropped dramatically this week – is it the perfect time to buy?
Jul 31, 2012 by Max MacalusoCloud Computing for Dogs, Cats, Iguanas, Parakeets…IDEXX Laboratories works the cloud.
Jul 28, 2012 by Max MacalusoIs This the End of MannKind?It might be time for investors to call it quits -- even if Afrezza is approved.
Jul 26, 2012 by Max MacalusoIs There Hope for MannKind?MannKind's Afrezza is at least a year away from FDA approval -- is it worth the wait?
Jul 17, 2012 by Max Macaluso1 Saucy Stock for Your PortfolioShould we add Don Draper's newest client to our portfolio?
Jul 17, 2012 by Max Macaluso3 Stocks That Will Sail Away With Your MoneyDon't sink your portfolio with these shipping companies.
Jul 9, 2012 by Max Macaluso3 Stocks for a Mad ManDon Draper is great at selling products, but is he also great at finding solid investments?
Jul 6, 2012 by Max MacalusoIs This Restaurant Stock Fried?Fourth-quarter earnings from Darden may have been sluggish, but there is still hope.
